Phase 3 PEACE-3 Study of Enzalutamide + Ra-223: Design

Evan Y. Yu, MD, discusses the design and objectives of the phase 3 PEACE 3 study, which evaluates the combination of enzalutamide (ENZA) and radium-223 (Ra-223) in androgen receptor pathway inhibitor (ARPI)–naive metastatic castration-resistant prostate cancer (mCRPC), focusing on its aim to assess the potential synergistic effects of this combination in improving patient outcomes, including overall survival and bone health.

EP: 1.Introduction & Case 1 Presentation: mHSPC

EP: 2.Newly diagnosed Diagnosed mHSPC: Goals of Therapy

EP: 3.Newly Diagnosed mHSPC: First-Line Treatment Options

EP: 4.Newly Diagnosed mHSPC: Androgen Receptor Pathway Inhibitor Selection

EP: 5.Case 1 Presentation (cont): mHSPC

EP: 6.Phase 3 ARANOTE Study of ADT + Darolutamide

EP: 7.Phase 3 ARANOTE Study of ADT + Darolutamide: Safety

EP: 8.mHSPC: Applying Data Toward Treatment Decision-Making

EP: 9.Adding Chemotherapy for a Patient Receiving ADT + an ARPI

EP: 10.Case 2 Presentation: mCRPC

EP: 11.Guideline-Directed Treatment Options: mCRPC

Now Viewing

EP: 12.Phase 3 PEACE-3 Study of Enzalutamide + Ra-223: Design

Video content above is prompted by the following:

Please review the design and objectives of the phase 3 PEACE 3 study of ENZA + Ra-223 for ARPI-naïve naive mCRPC.

Recent Videos